In this second article of his Cannabis Patent Review
series, Duane Morris partner Vince Capuano reports on recently granted U.S.
patents in various areas of cannabis technology.
He writes:
There are plenty of reports and testimonials on the medical
benefits of cannabis. Time, and better data, will determine whether
these benefits are realized, and whether some are overblown, and
the U.S. FDA will decide when the therapeutic uses of cannabinoids
are safe and effective, and approvable for human use in the U.S.
The FDA has approved CBD (cannabidiol), the principal
non-psychoactive constituent in cannabis, for the treatment of
certain types of seizures. The approval of Epidiolex (NDA Approval
Holder: GW Research Ltd.) brings the therapeutic use of CBD as an
active drug substance within the jurisdiction of the FDA. Thus,
because CBD is the active drug substance in an FDA-approved
pharmaceutical (Epidiolex), the FDA is currently considering
regulations for the testing
